Formoterol Fumarate And Budesonide Inhaler
| Product Name | Formoterol Fumarate and Budesonide Inhaler |
| Active Ingredients | Formoterol Fumarate + Budesonide |
| Dosage Form | Inhaler |
| Drug Class | Bronchodilator + Corticosteroid |
| Indication | Asthma and COPD |
| Administration | Inhalation Use |
| Prescription Required | Yes |
| Packaging | Metered Dose Inhaler |
Formoterol Fumarate And Budesonide Inhaler
Formoterol Fumarate and Budesonide Inhaler is a combination respiratory medication used for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It combines Budesonide, a corticosteroid that reduces airway inflammation, with Formoterol Fumarate, a long-acting bronchodilator that relaxes airway muscles. Together, they help improve breathing and prevent asthma symptoms.
This inhaler works by decreasing swelling and irritation in the airways while simultaneously widening bronchial passages for easier airflow. Regular use helps control symptoms such as wheezing, breathlessness, chest tightness, and persistent coughing. The dual-action formulation not only provides symptom relief but also helps prevent future asthma attacks and exacerbations.
Formoterol Fumarate and Budesonide Inhaler is designed for maintenance therapy and should be used consistently as prescribed by a healthcare professional. With proper inhalation technique and regular usage, patients experience improved lung function, better symptom control, and enhanced quality of life. It plays a vital role in maintaining respiratory stability and supporting long-term airway health.
Product Features
- Combination of Formoterol Fumarate and Budesonide
- Provides anti-inflammatory and bronchodilator action
- Helps maintain long-term asthma and COPD control
- Improves airflow and breathing comfort
- Convenient inhalation delivery system
How It Helps
- Reduces airway inflammation
- Relaxes airway muscles for easier breathing
- Prevents asthma attacks and flare-ups
- Improves overall lung function

Reviews
There are no reviews yet.